drugset
drugset / Trial / NCT03799926

Exploratory Study of ZG-801 for the Treatment of Hyperkalemia

NCT03799926 ↗

Phase 2 Completed 184 enrolled Zeria Pharmaceutical
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To investigate the efficacy of each ZG-801 starting dose and the titration algorithm of ZG-801 for the treatment of hyperkalemia in Japanese patients. To evaluate the safety of ZG-801 for the chronic use (total over 52 weeks). In addition, to confirm the safety after the discontinuation of ZG-801 treatment on 1 week follow-up.

Timeline

Start
2019-02-18
Primary completion
2019-11-06
Completion
2021-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Patiromer Other / unclassified 8.4 g Oral
Subject Patiromer Other / unclassified 16.8 g Oral

Indications

No indication recorded.